NovaBay Pharmaceuticals Ownership
| NBY Stock | USD 0.60 0.01 1.69% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
NovaBay |
NovaBay Stock Ownership Analysis
The book value of the company was now reported as 0.22. The company recorded a loss per share of 74.61. NovaBay Pharmaceuticals had not issued any dividends in recent years. The entity had 1:35 split on the 31st of May 2024. NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. Novabay Pharmaceuticals operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 29 people. To find out more about NovaBay Pharmaceuticals contact Justin Esq at 510 899 8800 or learn more at https://novabay.com.Besides selling stocks to institutional investors, NovaBay Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different NovaBay Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align NovaBay Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
NovaBay Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Less than 1% of NovaBay Pharmaceuticals are currently held by insiders. Unlike NovaBay Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against NovaBay Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of NovaBay Pharmaceuticals' insider trades
NovaBay Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NovaBay Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on NovaBay Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NovaBay Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Zheng Yongxiang over three months ago Acquisition by Zheng Yongxiang of 30000 shares of NovaBay Pharmaceuticals subject to Rule 16b-3 | ||
Zheng Yongxiang over six months ago Acquisition by Zheng Yongxiang of 30000 shares of NovaBay Pharmaceuticals subject to Rule 16b-3 | ||
Garlikov Julie over six months ago Acquisition by Garlikov Julie of 858 shares of NovaBay Pharmaceuticals subject to Rule 16b-3 | ||
Kunin Jeffrey over six months ago Acquisition by Kunin Jeffrey of 101650 shares of NovaBay Pharmaceuticals at 0.4625 subject to Rule 16b-3 | ||
Yenyou Zheng over six months ago Exercise or conversion by Yenyou Zheng of 30000 shares of NovaBay Pharmaceuticals subject to Rule 16b-3 | ||
Mijia Wu over a year ago Acquisition by Mijia Wu of 858 shares of NovaBay Pharmaceuticals subject to Rule 16b-3 | ||
Mijia Wu over a year ago Exercise or conversion by Mijia Wu of 858 shares of NovaBay Pharmaceuticals subject to Rule 16b-3 |
NovaBay Pharmaceuticals Outstanding Bonds
NovaBay Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. NovaBay Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most NovaBay bonds can be classified according to their maturity, which is the date when NovaBay Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| NOVARTIS CAPITAL P Corp BondUS66989HAS76 | View | |
| NOVARTIS CAPITAL P Corp BondUS66989HAQ11 | View | |
| NOVARTIS CAPITAL P Corp BondUS66989HAR93 | View | |
| NOVARTIS CAPITAL P Corp BondUS66989HAP38 | View | |
| NOVARTIS CAP P Corp BondUS66989HAN89 | View | |
| NOVARTIS CAP P Corp BondUS66989HAK41 | View | |
| NOVARTIS CAP P Corp BondUS66989HAJ77 | View | |
| US66981QAA40 Corp BondUS66981QAA40 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NovaBay Stock Analysis
When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.